

CITATION REPORT

List of articles citing

Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective

DOI: 10.3109/03009749609069986

Scandinavian Journal of Rheumatology, 1996, 25, 191-3.

Source: <https://exaly.com/paper-pdf/27666278/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
161	Atherosclerosis in SLE and Hughes syndrome. <i>Lupus</i> , 1997 , 6, 489-90	2.6	16
160	A multicentre study of 513 Danish patients with systemic lupus erythematosus. II. Disease mortality and clinical factors of prognostic value. <i>Clinical Rheumatology</i> , 1998 , 17, 478-84	3.9	84
159	Clinical significance of hemostatic markers and thrombomodulin in systemic lupus erythematosus: evidence for a prothrombotic state. <i>Lupus</i> , 1999 , 8, 737-41	2.6	23
158	Cerebral computed tomography and electroencephalography compared with neuropsychological findings in systemic lupus erythematosus. 1999 , 246, 706-11		39
157	Thrombosis in systemic lupus erythematosus: the role of antiphospholipid antibody. 1999 , 12, 212-9		9
156	Mortality and causes of death of 513 Danish patients with systemic lupus erythematosus. <i>Scandinavian Journal of Rheumatology</i> , 1999 , 28, 75-80	1.9	113
155	Dermatomyositis with splenic and renal infarctions during corticosteroid therapy. 2000 , 39, 512-6		3
154	The clinical significance of antiphospholipid antibodies in patients without autoimmune disease. 2000 , 30, 693-703		1
153	Treatment of the antiphospholipid antibody syndrome: progress in the last five years?. 2000 , 2, 256-61		12
152	Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort. <i>Lupus</i> , 2000 , 9, 170-5	2.6	173
151	Antiphospholipid (Hughes) syndrome in systemic lupus erythematosus. <i>Rheumatic Disease Clinics of North America</i> , 2000 , 26, 331-48	2.4	28
150	Hopkins Lupus Cohort. 1999 update. <i>Rheumatic Disease Clinics of North America</i> , 2000 , 26, 199-213, v	2.4	91
149	Which antiphospholipid antibody tests are most useful?. <i>Rheumatic Disease Clinics of North America</i> , 2001 , 27, 525-49	2.4	13
148	Management of thrombosis in antiphospholipid antibody syndrome. <i>Rheumatic Disease Clinics of North America</i> , 2001 , 27, 633-42, viii	2.4	22
147	Apoptosis in lupus pathogenesis. 2001 , 6, D1392-402		11
146	Lupus anticoagulant and history of thrombosis are not associated with persistent endothelial cell activation in systemic lupus erythematosus. 2001 , 125, 149-54		21
145	Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. <i>Lupus</i> , 2001 , 10, 401-4	2.6	275

144	A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. 2002 , 41, 924-9		236
143	Warning: thalidomide-related thrombotic risk potentially concerns patients with lupus. <i>Lupus</i> , 2002 , 11, 67-70	2.6	25
142	Intramuscular bleeding as a complication of anticoagulation treatment in a patient with systemic lupus erythematosus and antiphospholipid syndrome. 2002 , 8, 346-9		1
141	Treatment options for juvenile-onset systemic lupus erythematosus. 2002 , 4, 241-56		21
140	Antiphospholipid antibodies and stroke 2002 , 2, 120-133		
139	Analysis of risk factors and comorbid diseases in the development of thrombosis in patients with anticardiolipin antibodies. <i>Clinical Rheumatology</i> , 2003 , 22, 24-9	3.9	17
138	New approaches to prevention of thrombosis in the antiphospholipid syndrome: hopes, trials, and tribulations. 2003 , 48, 3004-8		31
137	[Plasma homocysteine levels in systemic lupus erythematosus]. 2003 , 120, 681-5		9
136	Clinical and laboratory evaluation of thrombophilia. 2003 , 24, 153-70		21
135	Síndrome antifosfolipídico. 2003 , 18, 78-84		
134	Does the anti-beta2-glycoprotein I antibody provide additional information in patients with thrombosis?. <i>Thrombosis Research</i> , 2003 , 111, 29-32	8.2	44
133	Treat juvenile-onset systemic lupus erythematosus according to disease severity. 2003 , 19, 11-15		
132	Connective tissue diseases in later life. 2003 , 13, 107-118		
131	Mesangial lupus nephritis in Chinese is associated with a high rate of transformation to higher grade nephritis. <i>Lupus</i> , 2003 , 12, 665-71	2.6	20
130	Leg ulcers of unusual causes. 2003 , 2, 207-16		6
129	Platelet-endothelial interactions: sepsis, HIT, and antiphospholipid syndrome. <i>Hematology American Society of Hematology Education Program</i> , 2003 , 2003, 497-519	3.1	93
128	Homocysteine, antiphospholipid antibodies and risk of thrombosis in patients with systemic lupus erythematosus. <i>Lupus</i> , 2004 , 13, 927-33	2.6	15
127	Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis. 2004 , 43, 28-36		113

126	Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXII. Predictors of time to the occurrence of initial damage. 2004 , 50, 3177-86		54
125	Manifestaciones clínicas y alteraciones inmunológicas en pacientes con síndrome antifosfolípido. Presentación de 112 casos. 2004 , 123, 466-470		
124	Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells: a pathway to targeted therapies. <i>Thrombosis Research</i> , 2004 , 114, 467-76	8.2	75
123	Molecular Pathogenesis of the Antiphospholipid Syndrome: Toward Novel Therapeutic Targets. 2005 , 377-391		
122	Risk factors for stroke among Filipino patients with systemic lupus erythematosus. 2005 , 8, 19-22		
121	Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005 , 19, 685-708	5.3	217
120	Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. 2005 , 52, 1473-80		261
119	Thrombosis in systemic lupus erythematosus: congenital and acquired risk factors. 2005 , 53, 452-9		59
118	Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. 2005 , 52, 2774-82		164
117	Antiphospholipid syndrome: review. 2005 , 98, 617-25; quiz 626-7, 645		15
116	Lupus in Baltimore: evidence-based clinical pearls from the Hopkins Lupus Cohort. <i>Lupus</i> , 2005 , 14, 970-86		39
115	[Antiphospholipid syndrome treatment, to whom, when and how long?]. 2005 , 1 Suppl 2, S52-8		1
114	Optimal use of antimalarials in treating cutaneous lupus erythematosus. 2005 , 6, 1-11		29
113	[Is it necessary to monitor blood hydroxychloroquine concentrations in patients with systemic lupus erythematosus?]. <i>Revue De Medecine Interne</i> , 2006 , 27, 655-7	0.1	2
112	Antiphospholipid syndrome and thrombosis. 2006 , 49, 861-74		13
111	Intra-vascular ultrasound findings of diffuse coronary atherosclerotic change in systemic lupus erythematosus with secondary antiphospholipid syndrome. 2006 , 70, 1082-5		3
110	Premature Atherosclerosis in Systemic Lupus Erythematosus: Pathogenesis and Therapeutic Considerations. 2006 , 8, 48-54		2
109	Anticoagulation strategies for treatment of ischemic stroke and antiphospholipid syndrome: case report and review of the literature. 2006 , 26, 1518-25		4

108	Management of antiphospholipid antibody syndrome: a systematic review. 2006 , 295, 1050-7		291
107	Antimalarials in systemic lupus erythematosus: benefits beyond disease activity. 2006 , 1, 225-233		5
106	Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. <i>Lupus</i> , 2006 , 15, 577-83	2.6	279
105	Antiphospholipid antibodies: a critical review of the literature. 2007 , 14, 494-9		26
104	New concepts in antimalarial use and mode of action in dermatology. 2007 , 20, 160-74		185
103	The treatment of antiphospholipid syndrome: a harmonic contrast. <i>Best Practice and Research in Clinical Rheumatology</i> , 2007 , 21, 1079-92	5.3	13
102	Vascular elasticity of systemic lupus erythematosus patients is associated with steroids and hydroxychloroquine treatment. 2007 , 1108, 24-34		35
101	Lupus nephritis and Raynaud's phenomenon are significant risk factors for vascular thrombosis in SLE patients with positive antiphospholipid antibodies. <i>Clinical Rheumatology</i> , 2008 , 27, 345-51	3.9	29
100	[Hydroxychloroquine and systemic lupus: a reappraisal]. <i>Revue De Medecine Interne</i> , 2008 , 29, 735-7	0.1	9
99	New developments in lupus-associated antiphospholipid syndrome. <i>Lupus</i> , 2008 , 17, 443-6	2.6	4
98	Twenty-two years of failure to set up undisputed assays to detect patients with the antiphospholipid syndrome. 2008 , 34, 347-55		33
97	Hydroxychloroquine: the cornerstone of lupus therapy. <i>Lupus</i> , 2008 , 17, 271-3	2.6	51
96	Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers. <i>Blood</i> , 2008 , 112, 1687-95	2.2	166
95	Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. 2009 , 61, 830-9		175
94	Systemic Lupus Erythematosus. 2009 , 131-159		2
93	Thrombosis in systemic lupus erythematosus: risk and protection. 2009 , 7, 1541-9		23
92	Chapter 15 Treatment of Thrombosis in the Antiphospholipid Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , 2009 , 185-191	0.3	
91	Chapter 14 Antiphospholipid Antibodies and Atherosclerosis. <i>Handbook of Systemic Autoimmune Diseases</i> , 2009 , 10, 169-183	0.3	

90	Current management of antiphospholipid syndrome-related thrombosis. 2009 , 7, 1551-8		7
89	Thromboprophylaxis and obstetric management of the antiphospholipid syndrome. 2009 , 10, 601-14		10
88	[High cardiovascular complications in systemic lupus erythematosus: physiopathology and risk management]. 2009 , 5, 595-602		1
87	Thrombophilic patterns of coagulation factors in lupus. <i>Lupus</i> , 2009 , 18, 400-6	2.6	14
86	The neurologic manifestations of systemic lupus erythematosus. 2009 , 15, 115-21		28
85	How I treat the antiphospholipid syndrome. <i>Blood</i> , 2009 , 114, 2020-30	2.2	65
84	Antiphospholipid antibodies and renal outcomes in patients with lupus nephritis. 2009 , 48, 1875-80		9
83	Microembolic signals in patients with systemic lupus erythematosus. 2010 , 37, 371-5		6
82	Antiphospholipid antibodies in critical illness. 2010 , 38, S51-6		8
81	Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. <i>Blood</i> , 2010 , 115, 2292-9	2.2	179
80	A novel antiphospholipid antibody agent?. <i>Blood</i> , 2010 , 115, 2124-5	2.2	6
79	The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. 2010 , 62, 863-8		203
78	The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis. <i>Lupus</i> , 2010 , 19, 460-9	2.6	103
77	Antiphospholipid syndrome and central nervous system. 2010 , 112, 602-8		27
76	[Hydroxychloroquine: a new therapeutic approach to the thrombotic manifestations of antiphospholipid syndrome]. <i>Revue De Medecine Interne</i> , 2010 , 31, 854-7	0.1	6
75	Clinical Neuroimmunology. 2011 ,		
74	Clinical research in systemic lupus erythematosus: immediate relevance to clinical practice. 2011 , 14, 1-5		5
73	Antimalarials and SLE. 2011 , 1061-1081		0

72	Treatment of Antiphospholipid Syndrome. 2011 , 1027-1042		
71	Pathophysiology of thrombosis and potential targeted therapies in antiphospholipid syndrome. 2011 , 9, 606-18		7
70	Hydroxychloroquine reduces binding of antiphospholipid antibodies to syncytiotrophoblasts and restores annexin A5 expression. 2011 , 205, 576.e7-14		47
69	Comparative assessment of vascular function in autoimmune rheumatic diseases: considerations of prevention and treatment. <i>Autoimmunity Reviews</i> , 2011 , 10, 416-25	13.6	83
68	ANTIPHOSPHOLIPID SYNDROME. 2011 , 344-360		2
67	Prevalence of annexin A5 resistance in children and adolescents with rheumatic diseases. <i>Journal of Rheumatology</i> , 2012 , 39, 382-8	4.1	3
66	Thrombosis in systemic lupus erythematosus: a review article. 2012 , 2012, 428269		31
65	[Management of antiphospholipid syndrome]. <i>Revue De Medecine Interne</i> , 2012 , 33, 217-22	0.1	4
64	Hydroxychloroquine: from malaria to autoimmunity. 2012 , 42, 145-53		348
63	Antiphospholipid syndrome in obstetrics. 2012 , 26, 65-76		45
62	Insights into the pathophysiology of the antiphospholipid syndrome provided by atomic force microscopy. 2012 , 43, 851-62		7
61	Latest advances in connective tissue disorders. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2013 , 5, 234-49	3.8	10
60	Multifaceted effects of hydroxychloroquine in human disease. <i>Seminars in Arthritis and Rheumatism</i> , 2013 , 43, 264-72	5.3	88
59	Atomic force microscopy: High resolution dynamic imaging of cellular and molecular structure in health and disease. <i>Journal of Cellular Physiology</i> , 2013 , 228, 1949-55	7	18
58	Transient ischemic attack and stroke in systemic lupus erythematosus. <i>Lupus</i> , 2013 , 22, 1251-8	2.6	27
57	Annexin A5 anticoagulant activity in children with systemic lupus erythematosus and the association with antibodies to domain I of β -glycoprotein I. <i>Lupus</i> , 2013 , 22, 702-11	2.6	17
56	Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review. <i>Blood</i> , 2013 , 122, 817-24	2.2	86
55	Thrombophilia in Systemic Lupus Erythematosus: A Review of Multiple Mechanisms and Resultant Clinical Outcomes. 2013 ,		

54	Infections increase risk of arterial and venous thromboses in Danish patients with systemic lupus erythematosus: 5102 patient-years of followup. <i>Journal of Rheumatology</i> , 2014 , 41, 1817-22	4.1	3
53	[Assessing the cardiovascular risk in patients with systemic lupus erythematosus]. <i>Revue De Medecine Interne</i> , 2014 , 35, 723-9	0.1	4
52	Osteonecrosis. 2014 ,		7
51	Risk factors for arterial thrombosis in antiphospholipid syndrome. <i>Thrombosis Research</i> , 2014 , 133, 173-68.2		32
50	Hydroxychloroquine: a multifaceted treatment in lupus. <i>Presse Medicale</i> , 2014 , 43, e167-80	2.2	101
49	Pathogenesis and treatment of atherosclerosis in lupus. <i>Rheumatic Disease Clinics of North America</i> , 2014 , 40, 475-95, viii	2.4	17
48	Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2015 , 14, 358-62	13.6	84
47	Glycated-H2A histone is better bound by serum anti-DNA autoantibodies in SLE patients: glycated-histones as likely trigger for SLE?. <i>Autoimmunity</i> , 2015 , 48, 19-28	3	14
46	Lupus eritematoso sistmico. <i>EMC - Aparato Locomotor</i> , 2015 , 48, 1-17	0	
45	Should very low doses of hydroxychloroquine and quinacrine be employed in combination for long-term maintenance of remission in systemic lupus to reduce the risk of ocular toxicity?. <i>Current Opinion in Rheumatology</i> , 2015 , 27, 213-5	5.3	6
44	Autoimmune therapeutic chloroquine lowers blood pressure and improves endothelial function in spontaneously hypertensive rats. <i>Pharmacological Research</i> , 2016 , 113, 384-394	10.2	13
43	The diagnosis and management of the haematologic manifestations of lupus. <i>Journal of Autoimmunity</i> , 2016 , 74, 139-160	15.5	53
42	Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives. <i>Drugs</i> , 2016 , 76, 459-83	12.1	91
41	Hydroxychloroquine-related retinal toxicity. <i>Rheumatology</i> , 2016 , 55, 957-67	3.9	57
40	Treatment of Thrombosis in Antiphospholipid Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , 2017 , 12, 231-241	0.3	
39	Antiphospholipid Antibodies and Atherosclerosis. <i>Handbook of Systemic Autoimmune Diseases</i> , 2017 , 12, 193-214	0.3	
38	Mechanisms of thrombosis in systemic lupus erythematosus and antiphospholipid syndrome. <i>Best Practice and Research in Clinical Rheumatology</i> , 2017 , 31, 334-341	5.3	28
37	Recurrent pregnancy loss. 2018 , 131-144		

36	HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2018 , 17, 1153-1168	13.6	43
35	Novel Insights in Systemic Lupus Erythematosus and Atherosclerosis. <i>Frontiers in Medicine</i> , 2017 , 4, 262	4.9	42
34	Systemic lupus erythematosus: Diagnosis and clinical management. <i>Journal of Autoimmunity</i> , 2019 , 96, 1-13	15.5	175
33	Anti-RNP/Sm antibodies in patients with systemic lupus erythematosus and its role in thrombosis: a case-control study. <i>Clinical Rheumatology</i> , 2019 , 38, 885-893	3.9	2
32	Loss of antiphospholipid antibody positivity post-thrombosis in SLE. <i>Lupus Science and Medicine</i> , 2020 , 7,	4.6	1
31	Leveraging the United States Epicenter to Provide Insights on COVID-19 in Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1971-1980	9.5	35
30	Anti-Neutrophil Extracellular Trap Antibodies and Impaired Neutrophil Extracellular Trap Degradation in Antiphospholipid Syndrome. <i>Arthritis and Rheumatology</i> , 2020 , 72, 2130-2135	9.5	22
29	Discontinuation of hydroxychloroquine in older patients with systemic lupus erythematosus: a multicenter retrospective study. <i>Arthritis Research and Therapy</i> , 2020 , 22, 191	5.7	8
28	Error in Reported Baricitinib Dose in the Article by Meesilpavikkai et al (Arthritis Rheumatol, May 2019). <i>Arthritis and Rheumatology</i> , 2020 , 72, 2135	9.5	
27	Error in Units of Measure on Figures in the Article by Li et al (Arthritis Rheumatol, July 2020). <i>Arthritis and Rheumatology</i> , 2020 , 72, 2135	9.5	
26	Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases. <i>Advances in Rheumatology</i> , 2020 , 60, 32	3	24
25	Cardiovascular Diseases and Rheumatology. 2021 , 353-381		
24	Association of Higher Hydroxychloroquine Blood Levels With Reduced Thrombosis Risk in Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2021 , 73, 997-1004	9.5	7
23	The Influence of an Elastase-Sensitive Complement C5 Variant on Lupus Nephritis and Its Flare. <i>Kidney International Reports</i> , 2021 , 6, 2105-2113	4.1	0
22	Poor Prognosis of COVID-19 Acute Respiratory Distress Syndrome in Lupus Erythematosus: Nationwide Cross-Sectional Population Study Of 252 119 Patients. <i>ACR Open Rheumatology</i> , 2021 , 3, 804-811	3.5	5
21	Accelerated Atherosclerosis in Antiphospholipid Syndrome. 2000 , 172-178		3
20	A population-based study of risk factors for heart failure in pediatric and adult-onset systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 527-533	5.3	2
19	Thrombophilia: what's a practitioner to do?. <i>Hematology American Society of Hematology Education Program</i> , 2001 , 322-38	3.1	10

18	Acute pretreatment with chloroquine attenuates renal I/R injury in rats. <i>PLoS ONE</i> , 2014 , 9, e92673	3.7	20
17	Coronavirus Disease-2019: Implication for the care and management of patients with systemic lupus erythematosus. <i>European Journal of Rheumatology</i> , 2020 , 7, S117-S120	1.7	22
16	Cardiovascular Disease in Patients With Systemic Lupus Erythematosus: Potential for Improved Primary Prevention With Statins. <i>Cardiology in Review</i> , 2021 , 29, 323-327	3.2	0
15	Thrombophilia: What's a Practitioner to Do?. <i>Hematology American Society of Hematology Education Program</i> , 2001 , 2001, 322-338	3.1	
14	Immunology of Atherosclerosis. 2001 ,		
13	Management of antiphospholipid syndrome in pregnancy. <i>Series in Maternal-fetal Medicine</i> , 2007 , 119-126		
12	Cardiac involvement in systemic lupus erythematosus. <i>Annales Universitatis Mariae Curie-Sklodowska Sectio D: Medicina</i> , 2008 , 63, 25-31		
11	Atherosclerosis in the Rheumatic Diseases: Compounding the Age Risk. 2011 , 17-25		
10	Systemic Autoimmune Diseases with Neurological Manifestations. 2011 , 375-389		
9	Cardiac and Vascular Disease in SLE. 2012 , 107-114		
8	Osteonecrosis and Intravascular Coagulation Revisited. 2014 , 71-80		
7	Antiphospholipid syndrome: an overview. <i>Cmaj</i> , 2003 , 168, 1675-82	3.5	26
6	Severe thrombotic events associated with pre-procedural interruption of anticoagulation in systemic lupus erythematosus with secondary antiphospholipid syndrome: Cases and literature review.. <i>Lupus</i> , 2022 , 9612033221074920	2.6	0
5	Hydroxychloroquine increased cholesterol transfer to high-density lipoprotein in systemic lupus erythematosus: A possible mechanism for the reversal of atherosclerosis in the disease.. <i>Lupus</i> , 2022 , 9612033221090127	2.6	0
4	Drug monitoring in systemic lupus erythematosus.. <i>Current Opinion in Pharmacology</i> , 2022 , 64, 102225	5.1	
3	Supplemental hydroxychloroquine therapy regulates adipokines in patients with systemic lupus erythematosus with stable disease. <i>Clinical Rheumatology</i> ,	3.9	
2	Fluctuation of Anti-Domain 1 and Anti- β Glycoprotein I Antibody Titers Over Time in Patients with Persistently Positive Antiphospholipid Antibodies.		0
1	Systemic Lupus Erythematosus. 2023 , 167-212		0

